CARACTERIZAÇÃO DOS ASPECTOS FÍSICOS DO SOLO DE ÁREA DEGRADADA, CASO DO BAIRRO VILA BURITI, MANAUS – AM

O objetivo deste trabalho foi realizar uma comparação dos aspectos físicos do solo entre uma área que sofreu terraplanagem e a que se encontra degradada. Dentre estes aspectos físicos estão a capacidade de infiltração e as taxas de penetração do solo. No bairro Vila Buriti, Manaus - AM, observou-se que a área havia sido terraplanada, tendo os horizontes O e A totalmente retirados, o que resultou na degradação da área, com a superfície do solo encrostada

CARACTERIZAÇÃO DOS ASPECTOS FÍSICOS DO SOLO DE ÁREA DEGRADADA, CASO DO BAIRRO VILA BURITI, MANAUS – AM

O objetivo deste trabalho foi realizar uma comparação dos aspectos físicos do solo entre uma área que sofreu terraplanagem e a que se encontra degradada. Dentre estes aspectos físicos estão a capacidade de infiltração e as taxas de penetração do solo. No bairro Vila Buriti, Manaus - AM, observou-se que a área havia sido terraplanada, tendo os horizontes O e A totalmente retirados, o que resultou na degradação da área, com a superfície do solo encrostada

Avaliacao tecnico economica do efeito residual da adubacao verde em sistemas de cultivo.

Made available in DSpace on 2018-02-23T00:29:53Z (GMT). No. of bitstreams: 1 Cienciaagronomica23.pdf: 4576667 bytes, checksum: 89503c7075346480b59993314d9e85cf (MD5) Previous issue date: 1996-10-30bitstream/item/173029/1/Ciencia-agronomica-23.pd

Criteria For The Diagnosis Of Alzheimer's Disease: Recommendations Of The Scientific Department Of Cognitive Neurology And Aging Of The Brazilian Academy Of Neurology [critérios Para O Diagnóstico De Doença De Alzheimer: Recomendações Do Departamento Científico De Neurologia Cognitiva E Do Envelhecimento Da Academia Brasileira De Neurologia]

This consensus prepared by the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology is aimed at recommending new criteria for the diagnosis of dementia and Alzheimer's disease (AD) in Brazil. A revision was performed of the proposals of clinical and of research criteria suggested by other institutions and international consensuses. The new proposal for the diagnosis of dementia does not necessarily require memory impairment if the cognitive or behavioral compromise affects at least two of the following domains: memory, executive function, speech, visual-spatial ability and change in personality. For the purpose of diagnosis, AD is divided into three phases: dementia, mild cognitive impairment and pre-clinical phase, where the latter only applies to clinical research. In the dementia picture, other initial forms were accepted which do not involve amnesia and require a neuroimaging examination. Cerebrospinal fluid biomarkers are recommended for study, but can be utilized as optional instruments, when deemed appropriate by the clinician.53146152Nitrini, R., Caramelli, P., Bottino, C.M., Damasceno, B.P., Brucki, S.M., Anghinah, R., Diagnóstico de doença de Alzheimer no Brasil: Critérios diagnósticos e exames complementares. Recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia (2005) Arq Neuropsiquiatr, 63, pp. 713-719. , Academia Brasileira de Neurologia(1994) Diagnostic and statistical manual of mental disorders, , American Psychiatric Association, 4 th Ed. Washington, DC: American Psychiatric AssociationMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology, 34, pp. 939-944Jack Jr., C.R., Albert, M.S., Knopman, D.S., Introduction to the recommendations from the National Institute on Aging and the Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease Alzheimer's & Dementia, , In pressPrice, J.L., McKeel Jr., D.W., Buckles, V.D., Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease (2009) Neurobiol Aging, 30, pp. 1026-1036Forlenza, O.V., Diniz, B.S., Gattaz, W.F., Diagnosis and biomarkers of predementia in Alzheimer's disease (2010) BMC Med., 8, p. 89Dubois, B., Feldman, H.H., Jacova, C., Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria (2007) Lancet Neurol, 6, pp. 734-746Dubois, B., Feldman, H.H., Jacova, C., Revising the definition of Alzheimer's disease: A new lexicon (2010) Lancet Neurol, 9, pp. 1118-1127Albert, M.S., DeKosky, S.T., Dickson, D., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimer's & Dementia, , In pressMcKhann, G.M., Knopman, D.S., Chertkow, H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimer's & Dementia, , In pressSperling, R.A., Aisen, P.S., Beckett, L.A., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup Alzheimer's & Dementia, , In pressClinical and neuropathological criteria for frontotemporal dementia (1994) J Neurol Neurosurg Psychiatry, 57, pp. 416-418. , The Lund and Manchester GroupsMcKeith, I.G., Dickson, D.W., Lowe, J., Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium (2005) Neurology, 65, pp. 1863-1872. , Consortium on DLB, McKeith IG, Dickson DW, Lowe JCummings, J.L., Benson, D.F., (1992) Dementia: A clinical approach, , 2 nd ed. Boston: Butterworth-HeinemanMesulam, M.M., (2000) Principles of behavioral and cognitive neurology, , 2 nd ed. New York: Oxford University PressHyman, B.T., Trojanowski, J.Q., Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease (1997) J Neuropathol Exp Neurol, 56, pp. 1095-1097Raicher, I., Caramelli, P., Diagnostic disclosure in Alzheimer's disease (2008) Dement Neuropsychol, 2, pp. 267-271Shimizu, M.M., Raicher, I., Takahashi, D.Y., Caramelli, P., Nitrini, R., Disclosure of the diagnosis of Alzheimer's disease: Caregivers' opinions in a Brazilian sample (2008) Arq Neuropsiquiatr, 66, pp. 625-630Raicher, I., Shimizu, M.M., Takahashi, D.Y., Nitrini, R., Caramelli, P., Alzheimer's disease diagnosis disclosure in Brazil: A survey of specialized physicians' current practice and attitudes (2008) Int Psychogeriatr, 20, pp. 471-481Raicher, I., Shimizu, M.M., Caramelli, P., Nitrini, R., Demências-enfoque multidisciplinar: Das bases fisiopatológicas ao diagnóstico e tratamento, , In: Brucki SMD, Magaldi RM, Morillo LS, et al. (eds). São Paulo: Editora Atheneuno prelo A revelação do diagnóstico de doença de Alzheimer(1987) Diagnostic and statistical manual of mental disorders, , American Psychiatric Association, 3 th Ed. Washington, D. C: American Psychiatric AssociationThe ICD-10 classification of mental and behavioral disorders (1993) Diagnostic criteria for research, , World Health Organization (WHO), Genova: World Health Organizatio

Efficacy and safety of combined piroxicam, dexamethasone, orphenadrine, and cyanocobalamin treatment in mandibular molar surgery

Third molar extraction is a common procedure frequently accompanied by moderate or severe pain, and involves sufficient numbers of patients to make studies relatively easy to perform. The aim of the present study was to determine the efficacy and safety of the therapeutic combination of 10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine citrate, and 2.5 mg cyanocobalamin (Rheumazin®) when compared with 20 mg piroxicam alone (Feldene®) in mandibular third molar surgery. Eighty patients scheduled for removal of the third molar were included in this randomized and double-blind study. They received (vo) Rheumazin or Feldene 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated with a measuring tape and adverse effects and patient satisfaction were recorded. There was no statistically significant difference in facial swelling between Rheumazin and Feldene (control group). Both drugs were equally effective in the control of pain, with Rheumazin displaying less adverse effects than Feldene. Therefore, Rheumazin appears to provide a better risk/benefit ratio in the mandibular molar surgery. Since the side effects resulting from nonsteroidal anti-inflammatory drug administration are a severe limitation to the routine use of these drugs in clinical practice, our results suggest that Rheumazin can be a good choice for third molar removal treatment